ALT logo

ALTIMMUNE INC

ALTNASDAQ
🏆 #2846 by market capEarnings Nov 4 · PreUS Equity
$670.05▼ $22.45 (−3.35%)
Simulated price
🔔
Track ALT
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.4%
7d▲ 19549.6%
14d▲ 20644.6%
30d▲ 21307.3%
ytd▲ 18486.7%
1y▲ 17626.2%
🏦Market Cap
$595M
Small Cap
📈Revenue Growth (YoY)
+55.0%
High Growth
📊Gross Margin
—
💵FCF Margin
439.0%
Strong
⚖️P/S Ratio
14517.7x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$665.98 – $675.76
52-Week Range
$2.56 – $6.44
Volume
$2.39B
Avg Volume
$1.70B
Shares Outstanding
194.5M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$41,000
Last Q Revenue
$11,047
P/E Ratio
—
P/S Ratio
14517.7x
EPS (TTM)
$-0.78
Dividend Yield
—
Dilution (1yr)
+41.2%

Why Investors Own ALT

  • ✓High-growth profile — revenue up +19.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 35% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ALT logo

ALTIMMUNE INC

ALT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$41K▲ +105.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$94M▼ −8.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$68M▼ −15.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
100.6M▲ +41.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$27M YoY
StockOtter · stockotter.space

About ALTIMMUNE INC

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Price Target

ⓘ
Average Target
$801.59
▲ +19.6% Upside
High Target$933.37
Low Target$679.27
Based on 31 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

ALTIMMUNE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ALT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

ALTIMMUNE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.